Prominent surgeon and cancer researcher Norman Wolmark has stepped down from leading positions at Allegheny Health Network and now will hold similar roles at the University of Pittsburgh and the UPMC Hillman Cancer Center.

He’s left his surgery practice and will become professor of surgery at the University of Pittsburgh School of Medicine. At Hillman Dr. Wolmark, 73, will fill the new position of director of National Cancer Institute cooperative group clinical trials.

He retains his role as chairman of the National Surgical Adjuvant Breast and Bowel Project, an independent clinical trials cooperative group he has led since 1994.

“It’s mutually beneficial,” Hillman Center director Dr. Robert Ferris said Tuesday. “It helps us put together grants for breast and bowel [cancer research].”

Advertise with us

In a public statement issued Friday, Dr. Wolmark said, “I look forward to applying the acclaimed expertise in precision medicine and genomic research currently available at the University of Pittsburgh to the clinical trials of the NSABP Foundation.”

Dr. Ferris said that as the only National Cancer Institute-designated Comprehensive Cancer Center in Western Pennsylvania, Hillman recently had its NCI grant renewed, and hopes to add its reach to NSABP clinical trials and benefit from Dr. Wolmark’s experience with NSABP.

Dr. Wolmark also continues as contact principal investigator of NRG Oncology, a group that combines NSABP, the Radiation Therapy Oncology Group and the Gynecologic Oncology Group.

“Our goal is to expand our clinical trials program with them, because we have our own clinical trials,” Dr. Ferris said, adding that Dr. Wolmark’s move would pave the way for the future of the organizations he leads.

“It helps for longevity and succession planning to be affiliated with a comprehensive cancer center,” Dr. Ferris said.

Advertise with us

“Norman had been there 40 years,” he said. “Contemplating a plan of success, it made sense to both of us [for him] to come on as a tenured faculty member.”

Dr. Wolmark had done research at Pitt in early clinical trials with noted breast cancer surgeon Dr. Bernard Fisher, who was NSABP chairman from 1967 to 1994. In 1993 Dr. Wolmark left Pitt and his work at Montefiore Hospital to become director of the Allegheny Cancer Center and director of surgical oncology at Allegheny General Hospital. His most recent position at Allegheny Health Network was as medical director of Breast Surgical Oncology, Cancer Research and Clinical Trials.

AHN Cancer Institute patients will continue to have full access to all NSABP and NRG clinical trials, according to AHN spokeswoman Stephanie Waite.

“AHNCI patients also have access to hundreds of clinical trials run by AHN physician-researchers and through our partnership with Johns Hopkins Kimmel Cancer Center,” she said, adding that many of the AHN Cancer Institute physicians, including Dr. Thomas Julian and Dr. Christie Hilton, hold leadership roles with NSABP and NRG and they will continue to design and run clinical trials at AHN.

The operations center of the NSABP will remain on the North Side; its biostatistical center, led by Joseph Costentino, will remain in Oakland. Dr. Ferris said Dr. Wolmark also will have an office at the Hillman Cancer Center.

Advertise with us

Several faculty oncologists at Hillman and UPMC have NSABP clinical trials going on right now, Dr. Ferris said. They receive funds from both NSABP and their permanent employers.

Clinical trial opportunities have grown, he said, citing the Institute for Precision Medicine, a collaboration between Pitt and UPMC.

“The capacity of the UPMC Genome Center is amazing,” Dr. Ferris said. “It’s a jewel, but it’s only as good as the number [of specimens] that go through it.” He said for now insurance will pay for some testing, but clinical trials are necessary to advance cancer treatment by identifying subgroups of patients and pinpointing effective treatments through precision medicine.

Jill Daly: jdaly@post-gazette.com.